Mankind Pharma (MANKIND) Q3 24/25 earnings summary

Executive summary

• Q3 and 9M FY25 marked a transformative period with the acquisition and integration of BSV, expanding into high-entry barrier and specialty R&D portfolios, and approval of unaudited standalone and consolidated financial results.

• Market share in IPM increased by 40 bps to 4.8% in December 2024, up from 4.4% in March 2024, driven by BSV acquisition.

• Four growth engines identified: base business, specialty chronic, OTC, and BSV's super specialty portfolio.

• Completed acquisition of Bharat Serums and Vaccines Limited (BSV) for INR 13,768 crores on October 23, 2024.

Financial highlights

• Q3 FY25 consolidated revenue at INR 3,230 crore, up 24% YoY; 9M FY25 consolidated revenue at INR 9,200 crore, up 17% YoY.

• Q3 FY25 EBITDA at INR 833 crore, up 36.4% YoY; adjusted EBITDA margin at 27.7%.

• Q3 FY25 PAT at INR 385 crore, down 16.4% YoY due to higher finance and amortization costs from acquisitions.

• Gross margin improved to 71% in Q3 FY25 from 68.3% YoY.

• Diluted EPS at INR 9.4 for Q3 FY25; cash EPS at INR 14.2.

Outlook and guidance

• BSV integration expected to deliver INR 50–100 crore in synergies over 12–24 months, mainly from MR productivity, manufacturing, and cross-selling.

• BSV business targeted for 15%+ growth with margins rising toward 30% over 2–5 years.

• Focus on expanding chronic and super specialty segments, leveraging BSV acquisition, and growing consumer healthcare.

• Corrective actions in field force and leadership expected to complete within Q4 FY25, setting up for stronger growth in FY26.

• Proceeds from QIP and NCD/CP issues are earmarked for debt repayment and future investments.